Pathology: mHNSCC - L1 - all population; mHNSCC - L1 - PDL1 positive;
| mHNSCC - L1 - all population | mHNSCC - L1 - PDL1 positive | |||
| KEYNOTE-048 (P vs C ; all population), 2019 | KEYNOTE-048 (P vs C ; CPS > 20), 2019 | KEYNOTE-048 (P vs C ; CPS > 1), 2019 | ||
| pembrolizumab alone | 3 | T1 | T1 | T1 |
| cetuximab plus platin plus 5FU | 0 | T0 | T0 | T0 |